Interview: Akari's Coversin Ticking Along Nicely
Phase II Trial Shows Promise For Rare Skin Disorder
Executive Summary
The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.